Primary central nervous system lymphoma: An update

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 550-558

  Soussain, Carole ^a   Hoang Xuan, Khê ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Central nervous system; Non hodgkin's lymphoma; Primary central nervous system lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN III; BETA INTEGRIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GELATINASE A; GELATINASE B; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERCELLULAR ADHESION MOLECULE 1; MELPHALAN; METHOTREXATE; PROCARBAZINE; PROTEIN BCL 6; RITUXIMAB; STAT6 PROTEIN; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VASCULOTROPIN; VINCRISTINE; X BOX BINDING PROTEIN 1;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN RADIATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC PROCEDURE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHOMA CELL; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SPECTROSCOPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE MODEL; LYMPHOMA; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 74049086073     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283310eb3     Document Type: Review

References (67)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO press: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp. 236-237.
2. Haldorsen IS, Kråkenes J, Krossnes BK, et al. CT and MR Imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 2009; 30:744-751.
3. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95:1504-1510.
4. Shibamoto Y, Ogino H, Suzuki G, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during, 1985-2004. Neuro Oncol 2008; 10:560-568.
5. Zacharia TT, Law M, Naldich TP, Leeds NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008; 18:411-417.
6. DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 1993; 33: 308-311.
7. Haque S, Law M, Abrey LE, Young RJ. Imaging of lymphoma of the central nervous system, spine, and orbit [Review]. Radiol Clin North Am 2008; 46:339-361; ix. (Pubitemid 351932047)
8. Akter M, Hiral T, Makino K, et al. Diffusion-weighted imaging of primary brain lymphomas: effect of ADC value and signal intensity of T2-weighted imaging. Comput Med Imaging Graph 2008; 32:539-543.
9. Raizer JJ, Koutcher JA, Abrey LE, et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 2005; 71:173-180.
10. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6:818-820; 840.
11. Karantanis D, O'eill BP, Subramaniam RM, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007;28:834-841.
12. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008; 10:223-228.
13. Taillibert S, Guillevin R, Menuel C, et al. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol 2008; 86:225-229. (Pubitemid 350263422)
14. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33:164-168. (Pubitemid 43152883)
15. Cassoux N, Giron A, Bodaghi B, et al. IL -10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2007; 48:3253-3259.
16. Ponzoni M, Berger F, Chassagne-Clement C, et al., International Extranodal Lymphoma Study Group. Reactive perivascular T-cell Infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 2007; 138:316-323.
17. Yang SH, Lee KS, Kim IS, et al. Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol 2009; 92:65-71.
18. Levy O, Deangelis LM, Filippa DA, et al. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 2008; 112:151-156.
19. Cady FM, O'Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are Indicators of an aggressive clinical course. J Clin Oncol 2008; 26:4814-4819.
20. Takeuch H, Matsuda K, Kital R, et al. Anglogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol 2007; 84:141-145. (Pubitemid 47202122)
21. Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107:190-196.
22. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107:3716-3723.
23. Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008; 22:400-405. (Pubitemid 351250546)
24. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111:3200-3210.
25. Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 2009; 22:547-555.
26. Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216:209-217.
27. Brunn A, Montesinos-Rongen M, Strack A, et al. Expression pattern and cellular sources of chemoklnes in primary central nervous system lymphoma. Acta Neuropathol 2007; 114:271-276. (Pubitemid 47226153)
28. Li J, Okamoto H, Yin C, et al. Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system. J Neurosurg 2008; 109:536-546.
29. Kinoshita M, Izumoto S, Hashimoto N, et al. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS Intravascular iymphomas. Brain Tumor Pathol 2008; 25:73-78.
30. Roy S, Josephson SA, Frldlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008; 26:96-105.
31. Sugita Y, Komatan H, Ohshlma K, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas. Oncol Rep 2007; 18:617-622. (Pubitemid 46614386)
32. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8:581-592.
33. Ferreri AJM, Ren M, Foppoli M, et al. Randomized phase II trial on primary chemotherapy with high-dose methotrexate alone or associated with high-dose cytarablne for patients with primary CNS lymphoma (IELSG #20 Trial): tolerability, activity and event-free survival analysis. Blood 2008; 112:580. (abstr).
34. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91:299-305.
35. Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002; 58:175-178.
36. Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008; 113:1025-1031.
37. Bessell EM, López-Guillermo A, Villá S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/ BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20:231-236. (Pubitemid 34032616)
38. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25:4730-4735. Erratum In: J Clin Oncol. 2008 Jan 10; 26(2):340. (Pubitemid 350086474)
39. Sierra del Rio M, Rousseau A, Soussain C, et al. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009; 14:526-539.
40. Angelov L, Doolittle ND, Kraemer DF, Siegal T, et al. Blood-brain barrier disruption and ntra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009; 27:3503-3509.
41. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituxlmab to standard chemotherapy improves the survival of both the germinal center B-cell-like and nongerminal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26:4587-4594.
42. Jahnke K, Muldoon LL, Varallyay CG, et al. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro Oncol 2009. [Epub ahead of print].
43. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of Intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350-1356. (Pubitemid 46706881)
44. Hong SJ, Kim JS, Chang JH, et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituxlmab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsel Med J 2009; 50:280-283.
45. Ferreri AJ, Crocchiolo R, Assanelli A, et al. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 2008; 49:2042-2047; Review.
46. Illerhaus G, Müller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93:147-148.
47. Soussain C, Hoang-Xuan K, Taillandier L, et al., Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moelle OsseuseThérapie Cellulaire. J Clin Oncol 2008; 26:2512-2518.
48. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007; 110:2528-2534. (Pubitemid 350174940)
49. Montemurro M, Kiefer T, Schüler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multlcenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18:665-671.
50. Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85:207-211. (Pubitemid 47629402)
51. Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20:319-325.
52. Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11:211-215.
53. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007;69:1178-1182. (Pubitemid 47517564)
54. Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86:211-215. (Pubitemid 350263420)
55. Ren M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96:864-867.
56. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with ntraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008; 71:1355-1360.
57. Kreisl TN, Panageas KS, EIkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system iymphoma. Leuk Lymphoma 2008; 49:1710-1716.
58. Gasser O, Bihl FK, Wolbers M, et al., Swiss HIV Cohort Study. HIV patients developing primary CNS lymphoma lack EBV-speciflc CD4+ T cell function irrespective of absolute CD4- T cell counts. PLoS Med 2007; 4:e96.
59. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Ketterlng Cancer Center prognostic model. J Clin Oncol 2006; 24:5711-5715. (Pubitemid 46631313)
60. Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62:548-555. (Pubitemid 38252794)
61. Linnebank M, Moskau S, Jürgens A, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009; 11:2-8.
62. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12:612-619.
63. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy [Review]. Oncologist 2008; 13:1285-1295.
64. Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of ntravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 2008; 49:4738-4745.
65. Soussain C, Muldoon LL, Varallyay C, et al. Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. Clin Cancer Res 2007; 13:2504-2511. (Pubitemid 46698603)
66. Kadoch C, Dinca EB, Volcu R, et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 2009; 15:1989-1997.
67. Touitou V, Daussy C, Bodaghi B, et al. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 2007; 48:3223-3229. (Pubitemid 351261167)